NCT01521559View on ClinicalTrials.gov

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

PHASE3CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

March 31, 2014

Conditions
Branch Retinal Vein Occlusion
Interventions
PROCEDURE

Macular Laser Photocoagulation

DRUG

Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

Trial Locations (56)

Unknown

Phoenix

Tucson

Beverly Hills

La Jolla

Mountain View

Palm Desert

Sacramento

Colorado Springs

Fort Myers

Miami

Plantation

Stuart

Tampa

Winter Haven

Augusta

Chicago

Baltimore (2 Locations)

Hagerstown

Boston (2 Locations)

Grand Rapids

Jackson

Southfield

Florissant

Lincoln

Las Vegas

Teaneck

Orchard Park

Syracuse

Charlotte

Oklahoma City

Portland

Kingston

West Mifflin

Florence

Ladson

West Columbia

Rapid City

Nashville

Abilene

Fort Worth

Harlingen

Houston

San Antonio

Seattle

Milwaukee

Vancouver

Victoria

Mississauga

Toronto

Urayasu-shi

Fukushima

Amagasaki

Kagoshima

Kyoto

Osaka

Hamamatsu

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01521559 - Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) | Biotech Hunter | Biotech Hunter